J. Mchutchison, E. Lawitz, M. Shiffman, A. Muir, G. Galler et al., Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection, New England Journal of Medicine, vol.361, issue.6, pp.580-593, 2009.
DOI : 10.1056/NEJMoa0808010

I. Jacobson, J. Mchutchison, G. Dusheiko, D. Bisceglie, A. Reddy et al., Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.364, issue.25, pp.2405-2416, 2011.
DOI : 10.1056/NEJMoa1012912

F. Poordad, J. Mccone, . Jr, B. Bacon, S. Bruno et al., Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011.
DOI : 10.1056/NEJMoa1010494

URL : https://hal.archives-ouvertes.fr/hal-00867494

E. Gane, C. Stedman, R. Hyland, X. Ding, E. Svarovskaia et al., Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C, New England Journal of Medicine, vol.368, issue.1, pp.34-44, 2013.
DOI : 10.1056/NEJMoa1208953

F. Poordad, C. Hézode, R. Trinh, K. Kowdley, S. Zeuzem et al., ABT-450/r???Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis, New England Journal of Medicine, vol.370, issue.21, pp.1973-1982, 2014.
DOI : 10.1056/NEJMoa1402869

URL : http://diposit.ub.edu/dspace/bitstream/2445/118403/1/661907.pdf

B. Maasoumy, K. Port, A. Markova, B. Serrano, M. Rogalska-taranta et al., Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting, PLoS ONE, vol.143, issue.2, p.23383319, 2013.
DOI : 10.1371/journal.pone.0055285.t004

S. Zeuzem, T. Asselah, P. Angus, J. Zarski, D. Larrey et al., Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection, Gastroenterology, vol.141, issue.6, pp.2047-2055, 2011.
DOI : 10.1053/j.gastro.2011.08.051

R. Schinazi, P. Halfon, P. Marcellin, and T. Asselah, HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, vol.15, issue.Suppl, pp.69-78, 2014.
DOI : 10.1517/14656566.2014.857656

URL : http://onlinelibrary.wiley.com/doi/10.1111/liv.12423/pdf

A. Usa, Recommendations for testing, managing, and treating hepatitis C. Available: http://www.hcvguidelines.org. Accessed 21, 2015.

P. Ruane, D. Ain, E. Stryker, R. Meshrekey, M. Soliman et al., Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry, Journal of Hepatology, vol.62, issue.5, pp.1040-1046, 2015.
DOI : 10.1016/j.jhep.2014.10.044

J. Fellay, A. Thompson, D. Ge, C. Gumbs, T. Urban et al., ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C, Nature, vol.18, issue.7287, pp.405-408, 2010.
DOI : 10.1001/jama.1957.72980250010016

A. Thompson, J. Fellay, K. Patel, H. Tillmann, S. Naggie et al., Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction, Gastroenterology, vol.139, issue.4, pp.1181-1189, 2010.
DOI : 10.1053/j.gastro.2010.06.016

H. Ochi, T. Maekawa, H. Abe, Y. Hayashida, R. Nakano et al., ITPA Polymorphism Affects Ribavirin-Induced Anemia and Outcomes of Therapy???A Genome-Wide Study of Japanese HCV Virus Patients, Gastroenterology, vol.139, issue.4, pp.1190-1197, 2010.
DOI : 10.1053/j.gastro.2010.06.071

Y. Hitomi, E. Cirulli, J. Fellay, J. Mchutchison, A. Thompson et al., Inosine Triphosphate Protects Against Ribavirin-Induced Adenosine Triphosphate Loss by Adenylosuccinate Synthase Function, Gastroenterology, vol.140, issue.4, pp.1314-1321, 2011.
DOI : 10.1053/j.gastro.2010.12.038

T. Asselah, E. Pasmant, and S. Lyoumi, Unraveling the genetic predisposition of ribavirin-induced anaemia, Journal of Hepatology, vol.53, issue.5, pp.971-973, 2010.
DOI : 10.1016/j.jhep.2010.06.007

S. Zeuzem, V. Soriano, T. Asselah, J. Bronowicki, A. Lohse et al., Faldaprevir and Deleobuvir for HCV Genotype 1 Infection, New England Journal of Medicine, vol.369, issue.7, pp.630-639, 2013.
DOI : 10.1056/NEJMoa1213557

J. Feld, K. Kowdley, E. Coakley, S. Sigal, D. Nelson et al., Treatment of HCV with ABT-450/r???Ombitasvir and Dasabuvir with Ribavirin, New England Journal of Medicine, vol.370, issue.17, pp.1594-1603, 2014.
DOI : 10.1056/NEJMoa1315722

P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo et al., ABT-450/r???Ombitasvir and Dasabuvir with or without Ribavirin for HCV, New England Journal of Medicine, vol.370, issue.21, pp.1983-1992, 2014.
DOI : 10.1056/NEJMoa1402338

C. Hézode, T. Asselah, K. Reddy, T. Hassanein, M. Berenguer et al., Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial, The Lancet, vol.385, issue.9986, pp.2502-2509, 2015.
DOI : 10.1016/S0140-6736(15)60159-3

M. Sulkowski, F. Poordad, M. Manns, J. Bronowicki, R. Reddy et al., Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial, Hepatology, vol.361, issue.3, pp.974-984, 2013.
DOI : 10.1056/NEJMoa0808010

P. Ferenci, T. Asselah, G. Foster, S. Zeuzem, C. Sarrazin et al., STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection, Journal of Hepatology, vol.62, issue.6, 2015.
DOI : 10.1016/j.jhep.2014.12.024

J. Holmes, S. Roberts, R. Ali, G. Dore, W. Sievert et al., genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response, Hepatology, vol.364, issue.1, pp.2152-2160, 2014.
DOI : 10.1056/NEJMoa1012912

URL : http://onlinelibrary.wiley.com/doi/10.1002/hep.27022/pdf

K. Chayama, C. Hayes, H. Abe, D. Miki, H. Ochi et al., IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C, The Journal of Infectious Diseases, vol.204, issue.1, pp.84-93, 2011.
DOI : 10.1093/infdis/jir210

E. Ogawa, N. Furusyo, M. Nakamuta, E. Kajiwara, H. Nomura et al., Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy, Journal of Hepatology, vol.59, issue.4, pp.667-674, 2013.
DOI : 10.1016/j.jhep.2013.05.017

A. Thompson, A. Muir, M. Sulkowski, D. Ge, J. Fellay et al., Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus, Gastroenterology, vol.139, issue.1, pp.120-129, 2010.
DOI : 10.1053/j.gastro.2010.04.013

E. Estrabaud, M. Vidaud, P. Marcellin, and T. Asselah, Genomics and HCV infection: Progression of fibrosis and treatment response, Journal of Hepatology, vol.57, issue.5, pp.1110-1125, 2012.
DOI : 10.1016/j.jhep.2012.05.016

N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin et al., Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection, New England Journal of Medicine, vol.370, issue.20, pp.1889-1898, 2014.
DOI : 10.1056/NEJMoa1402454

URL : http://diposit.ub.edu/dspace/bitstream/2445/118704/1/661902.pdf